Centogene N.V. - רווח נקי למניה בארבעת הרבעונים האחרונים CNTG

Centogene N.V. is a recognized global authority in the diagnosis of hereditary pathologies, possessing an invaluable array of genetic mutations. Big Data analytics create a robust defensive barrier for partners, ensuring high margins and a stable cash flow. Growth is driven by the demand from pharma behemoths for the AI platform while maintaining liquidity. The GURU.Markets terminal displays the EPS dynamics on a trailing twelve months (TTM) basis, where the current figure is -233.70.

Year-over-year (YoY) EPS growth (TTM) measures the change in net profit per share over a rolling twelve-month period. Analyzing the percentage dynamics of EPS YoY TTM allows for the determination of the actual business scaling speed relative to the market sector. A positive trend confirms operational efficiency and the resilience of the monetization model. For Centogene N.V. (CNTG), this indicator is critical, as it reflects the ability to generate profit despite geopolitical barriers and restrictions on the cross-border transfer of biomaterials.